These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 1480778)

  • 1. Treatment acceleration in radiotherapy: the relative time factors and dose-response slopes for tumours and normal tissues.
    Hendry JH
    Radiother Oncol; 1992 Dec; 25(4):308-12. PubMed ID: 1480778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fractionation sensitivities and dose-control relations of head and neck carcinomas: analysis of the randomized hyperfractionation trials.
    Stuschke M; Thames HD
    Radiother Oncol; 1999 May; 51(2):113-21. PubMed ID: 10435801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The potential for sparing of parotids and escalation of biologically effective dose with intensity-modulated radiation treatments of head and neck cancers: a treatment design study.
    Wu Q; Manning M; Schmidt-Ullrich R; Mohan R
    Int J Radiat Oncol Biol Phys; 2000 Jan; 46(1):195-205. PubMed ID: 10656393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Late effects of hyperfractionated radiotherapy for advanced head and neck cancer: long-term follow-up results of RTOG 83-13.
    Fu KK; Pajak TF; Marcial VA; Ortiz HG; Rotman M; Asbell SO; Coia LR; Vora NL; Byhardt R; Rubin P
    Int J Radiat Oncol Biol Phys; 1995 Jun; 32(3):577-88. PubMed ID: 7790242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apparent rates of proliferation of acutely responding normal tissues during radiotherapy of head and neck cancer.
    Fowler JF
    Int J Radiat Oncol Biol Phys; 1991 Nov; 21(6):1451-6. PubMed ID: 1938553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [SIB-IMRT radiotherapy given concomitantly with cisplatin for locally advanced squamous cell head and neck cancer (SCHNC). Evaluation of the early results and toxicity].
    Kiprian D; Jarząbski A; Pawłowska B; Michalski W; Kawecki A
    Otolaryngol Pol; 2011 Sep; 65(5 Suppl):117-25. PubMed ID: 22000261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Local control, TCD50 and dose-time prescription habits in radiotherapy of head and neck tumours.
    Dubben HH
    Radiother Oncol; 1994 Sep; 32(3):197-200. PubMed ID: 7816938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Volume and heterogeneity dependence of the dose-response relationship for head and neck tumours.
    Agren Cronqvist AK; Källman P; Turesson I; Brahme A
    Acta Oncol; 1995; 34(6):851-60. PubMed ID: 7576755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
    Lauve A; Morris M; Schmidt-Ullrich R; Wu Q; Mohan R; Abayomi O; Buck D; Holdford D; Dawson K; Dinardo L; Reiter E
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):374-87. PubMed ID: 15380569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Normal tissue tolerance to external beam radiation therapy: larynx and pharynx].
    Debelleix C; Pointreau Y; Lafond C; Denis F; Calais G; Bourhis JH
    Cancer Radiother; 2010 Jul; 14(4-5):301-6. PubMed ID: 20598610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of overall treatment time and radiobiological parameters on biologically effective doses in cervical cancer patients treated with radiation therapy alone.
    Gasinska A; Fowler JF; Lind BK; Urbanski K
    Acta Oncol; 2004; 43(7):657-66. PubMed ID: 15545186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evaluation of mucosal acute radiation injury during accelerated-hyperfractionted split course radiotherapy (CHA-CHA) in advanced head and neck neoplasms].
    Miszczyk L; Tarnawski R; Woźniak G; Maciejewski B
    Otolaryngol Pol; 2002; 56(5):543-9. PubMed ID: 12523161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concomitant cisplatin and radiotherapy in a conventional and modified fractionation schedule in locally advanced head and neck cancer: a randomised phase II EORTC trial.
    Bartelink H; Van den Bogaert W; Horiot JC; Jager J; van Glabbeke M
    Eur J Cancer; 2002 Mar; 38(5):667-73. PubMed ID: 11916549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase I/II trial of two variants of accelerated fractionated radiotherapy regimens for advanced head and neck cancer: results of RTOG 88-09.
    Fu KK; Clery M; Ang KK; Byhardt RW; Maor MH; Beitler JJ
    Int J Radiat Oncol Biol Phys; 1995 Jun; 32(3):589-97. PubMed ID: 7790243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor control probability (TCP) and normal tissue complication probability (NTCP) in head and neck cancer.
    Grégoire V
    Rays; 2005; 30(2):105-8. PubMed ID: 16294902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accuracy requirements for head and neck intensity-modulated radiation therapy based on observed dose response of the major salivary glands.
    Kapanen M; Collan J; Saarilahti K; Heikkonen J; Kairemo K; Tenhunen M
    Radiother Oncol; 2009 Oct; 93(1):109-14. PubMed ID: 19435641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiotherapy by multiple fractions per day (MFD) in head and neck cancer: acute reactions of skin and mucosa.
    Van der Schueren E; Van den Bogaert W; Vanuytsel L; Van Limbergen E
    Int J Radiat Oncol Biol Phys; 1990 Aug; 19(2):301-11. PubMed ID: 2394609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Causes of failure of radiotherapy in head and neck cancer.
    Peters LJ; Fletcher GH
    Radiother Oncol; 1983 Aug; 1(1):53-63. PubMed ID: 6680213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative dose-volume response analysis of changes in parotid gland function after radiotherapy in the head-and-neck region.
    Roesink JM; Moerland MA; Battermann JJ; Hordijk GJ; Terhaard CH
    Int J Radiat Oncol Biol Phys; 2001 Nov; 51(4):938-46. PubMed ID: 11704314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time factors in larynx tumor radiotherapy: lag times and intertumor heterogeneity in clinical datasets from four centers.
    Roberts SA; Hendry JH
    Int J Radiat Oncol Biol Phys; 1999 Dec; 45(5):1247-57. PubMed ID: 10613320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.